Chemistry Ventures, the San Francisco-based firm founded by veterans from Bessemer Venture Partners, Index Ventures, and Andreessen Horowitz, is raising $500 million for its second fund—a significant bet that specialized, thesis-driven investing can outperform in an era of massive capital concentration. The firm's founding team includes operators who explicitly rejected the megafund playbook, instead focusing on early-stage companies in specific sectors where deep domain expertise and founder relationships matter more than check size. This move arrives as North American startup funding reached $392 billion in the first half of 2026, according to Crunchbase data, though observers should note this figure conflates reported and estimated deals across databases with varying verification standards. The actual deployed capital and fund closures may tell a different story than headline billions suggest.
The $392 billion influx reflects a market heavily skewed toward AI. But beneath that aggregate number lies a structural inversion: while megafunds like Sequoia, Andreessen Horowitz, and Benchmark are deploying increasingly large tickets into later-stage AI companies and infrastructure plays, they're also pulling attention and capital density away from seed and Series A rounds. Chemistry's thesis appears to be that this creates a vacuum for specialized funds with expertise in specific AI applications—say, enterprise vertical solutions or AI-enabled hardware—where a $50 million fund can move decisively and establish ownership stakes that megafunds ignore. Simultaneously, LP behavior has shifted toward concentration itself: risk-averse limited partners, spooked by economic uncertainty, are funneling capital into the largest vehicles they perceive as 'safer,' even as historical data shows that venture's best returns come from smaller, focused funds with asymmetric upside potential.
Chemistry's fundraise signals growing founder frustration with megafund dynamics. Larger funds require larger check sizes and faster scaling timelines, forcing founders into premature growth moves that destroy unit economics. Specialized funds like Chemistry can afford to let portfolio companies optimize for profitability, retention, and sustainable growth—metrics that matter far more than topline ARR in AI software where differentiation erodes rapidly. The unintended consequence of LP flight to megafunds is that founders in non-obvious AI categories now face a choice: accept megafund capital and its accompanying pressure to scale into unprofitable scale, or work with smaller firms that understand their market but lack the $5 billion+ dry powder for later rounds. This capital bifurcation threatens to hollow out middle-market AI companies that need $200 million in total funding—too large for specialty funds, too small to move the needle for the largest players.